Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers

Arzneimittel-Forschung/Drug Research

Volumn 59, Issue 12, 2009, Pages 651-658

  Bonn, Michael ^a   Eydeler, Urte ^b   Barkworth, Martin ^b   Rovati, Lucio C ^c  

^a Madaus AG   (Germany)

^b Scope International GmbH   (Germany)

^c Rotta Research Laboratorium   (Italy)

Author keywords

Bellissima ; Bioequivalence; CAS 302 22 7; CAS 57 63 6; Chlormadinone acetate; Ethinylestradiol

Indexed keywords

BELLISSIMA; CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL; PARACETAMOL; UNCLASSIFIED DRUG;

ACNE; ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD SAMPLING; BREAKTHROUGH BLEEDING; BREAST TENSION; CLINICAL TRIAL; COMEDO; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; FATIGUE; FEMALE; FILM COATING; HAY FEVER; HOARSENESS; HUMAN; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE DRUG DOSE; TABLET FORMULATION; TANDEM MASS SPECTROMETRY; VOMITING;

EID: 74249103600     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296455     Document Type: Article

References (18)

1. Brody SA, Turkes A, Goldzieher JW. Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 μg and three norethindrone/ethinyl estradiol-35 l g OC formulations: are "low-dose" pills really lower? Contraception. 1989;40:269-84.
2. Orme MLE, Back DJ, Breckenridge AM. Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet. 1983;8:95-136.
3. Goldzieher JW, Brody SA. Pharmacokinetics of ethinyl estradiol and mestranol. Am J Obstet Gynecol. 1990;163: 2114-9.
4. Stead RJ, Grimmer SFM, Rogers SM, et al . Pharmacokinetics of contraceptive steroids in patients with cystic fibrosis. Thorax. 1987;42:59-64.
5. Beier HM, Beier-Hellwig K: Chlormadinonacetat - ein pro- gesteronähnliches Gestagen mit antiandrogener Partialwirkung in der oralen Kontrazeption. J Reproduktionsmed Endokrinol. 2004;1(4):308-17
6. Note for Guidance on the Investigation of Bioavailability and Bioequivalence. Committee for Proprietary Medicinal Products. CPMP/EWP/QWP/1401/98. London; 26 July 2001.
7. SAS Institute Inc. SAS/STAT User's Guide, Release 6.03 Edition. The GLM Procedure. Cary, NC: SAS Institute Inc.; 1998.
8. United States Pharmacopeia XXIII. National Formulary 18 No 1090. In Vivo Bioequivalence Guidances. 4382-4387.
9. Diletti E, Hauschke D, Steinijans VW. Sample size determination for bioequivalence assessment by means of confidence intervals. Int J Clin Pharmacol Ther Toxicol. 1992; 30(suppl. 1):51-8
10. Shapiro SS, Wilk MB. An analysis of variance test for normality. Biometrika. 1965;52:591.
11. Chow SC, Liu JP. Designs and Analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker Inc.; 1992.
12. Hollander M, Wolfe DA. Nonparametric statistical methods. The two sample problem. New York: Wiley; 1973.
13. Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1991;29(suppl. 1): 1-8.
14. Lund RE. Tables for an approximate test for outliers in linear models. Technometrics. 1975;17(4):473-6.
15. USP 23. In Vivo Bioequivalence Guidances/General Information. 1929 ff.
16. Bock K, Heskamp ML, Schramm G. Ergebnisse der BEDYStudie: Überzeugender Einfluss von CMA bei Dysmenorrhoen und anderen zyklusabhängigen Beschwerden. gyne. 2008;19 Suppl:219-25.
17. Kerscher M, Reuther T, Schramm G. Chlormadinonacetat enthaltende Mikropille verbessert unreine Haut. Frauenarzt. 2007;48:373-8.
18. Schramm G, Waldmann-Rex S. Die TeeNIS-Studie. gyne. 2009;11:19-21.